Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol

Patients completing 52-weeks of tirzepatide therapy on the IVIM protocol experienced significant weight loss with a high level of treatment adherence and program utilization. The findings suggest that individualized dose titration and frequent access to support may improve outcomes of patients initiated on weight reduction therapy with GLP-1 medications. These findings support the IVIM protocol as a safe, effective and individualized model for delivering obesity treatment through a curated, patient-centered, virtual approach.